EUCTR2010-022258-17-ES进行中（未招募）不适用
Efecto de niacina/laropiprant en la concentración de lipoproteína (A) en relación a las concentraciones basales y al tamaño de lipoproteína (A).
Instituto Aragonés de Ciencias de la Salud0 个研究点开始时间: 2011年2月22日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Edad >18 y <65 años
- •2. Cifras de LDLc entre 70 y 190 mg/dl.
- •3. Cifras de triglicéridos < 500 mg/dl.
- •4. Disponibilidad de al menos 2 determinaciones de Lp(a) previas al comienzo del estudio sin diferencias > 20 % o >20 mg/dl.
- •5. Ausencia de fármacos hipolipemiantes o dosis estables en los últimos 3 meses.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Enfermedad hepática o enzimas hepáticas > 2 veces superiores a los valores de referencia.
- •2. Valores de creatinina > 2 mg/dl.
- •3. Úlcera péptica activa.
- •4. Episodio de gota en el último año.
- •5. Diabetes mellitus no controlada (HbA1c > 8%).
- •6. Participación en otro ensayo clínico en los 3 meses previos al comienzo del estudio.
研究者
相似试验
尚未招募
4 期
Abnormal serum triglyceride(form of fat)& low HDL cholesterol, important risk factors for heart & blood vessel diseases. Niacin, lipid lowering drug, is less used due to its side effects, can be minimized by adding Laropiprant. We study the drugs effect on both serum triglyceride & low HDL levelsCTRI/2011/08/001977Sub arm study of PURSE HIS funded by Department of Science and Technology Government of India50
招募中
2 期
The effect of niacin in the treatment of depressioIRCT20231207060286N1Ahvaz University of Medical Sciences66
进行中（未招募）
1 期
The effect of Niaspan (slow release nicotinic acid) on plasma phosphate, and renal phosphate handling in patents with severe chronic kidney disease - Niaspan in CKDChronic renal failure (CKD stages 4 &%)EUCTR2005-002982-35-GBBarts and The London NHS Trust
进行中（未招募）
1 期
Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study) - NICOLaipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated Lp(a) levels include nicotinic acid (niacin), but there is a lack of randomised controlled studies assessing the effectiveness of these therapies in lowering Lp(a) as a primary endpoint and in reducing cardiovascular events in the long term.EUCTR2006-005710-12-DECharité Universitätsmedizin Berlin150
尚未招募
Unknown
Effect of nicotinamide riboside supplementation in dilated cardiomyopathy patients to CERP, Chromadex Inc. USACTRI/2023/04/051385Chromadex Inc. USA